Lumos Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Lumos Pharma CEO'su Rick Hawkins, Jan2011 tarihinde atandı, in görev süresi 13.83 yıldır. in toplam yıllık tazminatı $ 952.87K olup, şirket hissesi ve opsiyonları dahil olmak üzere 61.1% maaş ve 38.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 9.19% ine doğrudan sahiptir ve bu hisseler $ 3.30M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.6 yıl ve 8.7 yıldır.

Anahtar bilgiler

Rick Hawkins

İcra Kurulu Başkanı

US$952.9k

Toplam tazminat

CEO maaş yüzdesi	61.1%
CEO görev süresi	13.8yrs
CEO sahipliği	9.2%
Yönetim ortalama görev süresi	4.6yrs
Yönetim Kurulu ortalama görev süresi	8.7yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Mar 22

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Nov 04

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Dec 09

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Nov 17

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

CEO Tazminat Analizi

Rick Hawkins'un ücretlendirmesi Lumos Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$36m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$953k	US$583k	-US$34m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$1m	US$582k	-US$31m
Sep 30 2022	n/a	n/a	-US$28m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	n/a	n/a	-US$30m
Dec 31 2021	US$1m	US$571k	-US$30m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$2m	US$516k	-US$6m

Tazminat ve Piyasa: Rick 'nin toplam tazminatı ($USD 952.87K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 656.26K ).

Tazminat ve Kazançlar: Rick 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Rick Hawkins (75 yo)

13.8yrs

Görev süresi

US$952,869

Tazminat

Mr. Richard J. Hawkins, also known as Rick, is Operating Partner of Havencrest Healthcare Partners. He is the Founder of Lumos Pharma, Inc. and has been its Chairman of the Board since March 26, 2020, its...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Hawkins	Founder	13.8yrs	US$952.87k	9.19% $ 3.3m
John McKew	Chief Scientific Officer & President	8.6yrs	US$904.79k	0.039% $ 13.8k
Lori Lawley	CFO & Principal Accounting Officer	4.7yrs	US$569.78k	0.11% $ 39.2k
Lisa Miller	Senior Director of Investor Relations	no data	Veri yok	Veri yok
Bradley Powers	Chief Compliance Officer & General Counsel	9.3yrs	US$853.06k	0.050% $ 18.1k
Aaron Schuchart	Chief Business Officer	4.5yrs	Veri yok	0.052% $ 18.8k
Pisit Pitukcheewanont	Chief Medical Officer	1.4yrs	Veri yok	0.060% $ 21.4k
Alpa Parikh	Senior Vice President of CMC & Supply Management	less than a year	Veri yok	Veri yok
Eddie Varnado	Corporate Controller	3.6yrs	Veri yok	Veri yok

4.6yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: LUMO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Hawkins	Founder	13.8yrs	US$952.87k	9.19% $ 3.3m
Lota Zoth	Independent Director	12yrs	US$69.33k	0.027% $ 9.7k
Joseph S. McCracken	Independent Director	4.7yrs	US$56.33k	0.19% $ 69.4k
Kevin Lalande	Independent Director	10.8yrs	US$54.33k	0.013% $ 4.7k
Thomas Raffin	Lead Independent Director	25.8yrs	US$86.83k	0.12% $ 41.5k
George Werther	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Chad Johnson	Independent Director	6.7yrs	US$64.33k	0.013% $ 4.7k
An van Es-Johansson	Independent Director	3.8yrs	US$52.83k	0.011% $ 3.8k
Ron Rosenfeld	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Peter Clayton	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Reiko Horikawa	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Mark Bach	Scientific Advisory Board Member	3.3yrs	Veri yok	Veri yok

8.7yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LUMO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.7 yıldır).

Lumos Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer

Lumos Pharma, Inc. Announces Departure of David B. Karpf, Chief Medical Officer, Effective June 29, 2023

Insider recently sold US$611k worth of stock

Insider recently bought US$455k worth of stock

Independent Director recently bought US$56k worth of stock

Lumos Pharma, Inc. Announces Board Changes

Recent updates

Double Point Ventures LLC entered into a definitive merger agreement to acquire Lumos Pharma, Inc. (NasdaqGM:LUMO) for $36.9 million.

Lumos Pharma, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024

We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 11%

Lumos Pharma, Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 15% to US$23.33

Lumos Pharma, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer

Consensus revenue estimates decrease by 20%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Lumos Pharma Announces New Data and Analysis of 15 Subjects from Oragrowth212 Trial Presented At the 2023 ESPE Annual Meeting

Lumos Pharma, Inc. Announces Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

Price target increased by 13% to US$20.25

We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

First quarter 2023 earnings released: US$0.89 loss per share (vs US$0.92 loss in 1Q 2022)

Consensus revenue estimates increase by 43%, EPS downgraded

Lumos Pharma, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Lumos Pharma, Inc. Announces Departure of David B. Karpf, Chief Medical Officer, Effective June 29, 2023

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

New minor risk - Share price stability

Insider recently sold US$611k worth of stock

Insider recently bought US$455k worth of stock

Lumos Pharma, Inc. Announces Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

Consensus revenue estimates increase by 99%

Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 17%

Lumos Pharma, Inc. to Report Fiscal Year 2022 Results on Mar 01, 2023

Consensus revenue estimates increase by 66%

Price target decreased to US$21.83

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral Lum-201 for Moderate Pediatric Growth Hormone Deficiency

Lumos Pharma, Inc. (NasdaqGM:LUMO) announces an Equity Buyback for $3 million worth of its shares.

Lumos Pharma announces new buyback program

Lumos Pharma, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Consensus forecasts updated

Lumos Pharma, Inc. Announces Clinical Development Updates

Price target decreased to US$25.00

Lumos Pharma, Inc. Reaches 50% Randomization Milestone in Phase 2 Oragrowth210 Trial Evaluating Oral Lum-201 in Pghd

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$25.00

Lumos Pharma, Inc. to Report Fiscal Year 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.90 loss per share (vs US$0.21 profit in 3Q 2020)

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Independent Director recently bought US$56k worth of stock

First half 2021 earnings released: US$2.08 loss per share (vs US$1.08 loss in 1H 2020)

Price target decreased to US$27.67

Lumos Pharma, Inc. Announces New Data Highlights from Three Patients with Pediatric Growth Hormone Deficiency

Chief Medical Officer has left the company

Lumos Pharma, Inc. Announces Results of Peer-Reviewed Analyses of Data from Two Prior Pediatric Growth Hormone Deficiency

New 90-day low: US$14.97

Independent Director has left the company

Lumos Pharma, Inc. to Report Fiscal Year 2020 Results on Mar 09, 2021

Lumos Pharma, Inc. Announces Board Changes

Lumos Pharma, Inc. Announces Resignation of Eugene P. Kennedy as Chief Medical Officer, Effective March 6, 2021

New 90-day high: US$17.47

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

New 90-day high: US$15.80

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Analysts increase revenue estimates to US$60.7k

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Lumos Pharma, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Analysts lower revenue estimates to US$2.65m

Lumos Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020

CEO Tazminat Analizi

CEO

Görev süresi